DRTS Stock Chart & Stats
4520.00
50.00(1.12%)
―
--
Day’s Range― - ―
52-Week Range4,150.00 - 4,800.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)4.45K
Market Cap
₪4.07B
Enterprise Value1.05K
Total Cash (Recent Filing)₪100.64M
Total Debt (Recent Filing)₪15.15M
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Nov 24, 2026EPS Estimate
-44.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.04
Shares Outstanding90,325,874
10 Day Avg. Volume3,774
30 Day Avg. Volume4,451
Financial Highlights & Ratios
PEG Ratio-0.53
Price to Book (P/B)5.17
Price to Sales (P/S)0.00
P/FCF Ratio-12.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₪5,449.49Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-264.24
Revenue Forecast (FY)₪340.61M
Bulls Say, Bears Say
Bulls Say
Localized Alpha-Radiation TechnologyAlpha DaRT is designed to concentrate high-energy radiation within or near tumors while limiting exposure to surrounding healthy tissue. If clinical evidence continues to support this profile, the differentiated delivery approach could support use across multiple solid-tumor indications.
Encouraging Combination-Therapy DataThe reported head and neck results provide an early clinical signal for combining Alpha DaRT with pembrolizumab, including no serious Alpha DaRT-related adverse events. Although the cohort is small, the findings support larger trials and the company’s immuno-oncology strategy.
Advancing Pancreatic Cancer ProgramCompleting enrollment in a multicenter pancreatic cancer study advances Alpha DaRT from recruitment toward data maturation and potential pivotal-trial planning. The expanded 48-patient design and international site footprint create a more substantial clinical foundation for future development decisions.
Bears Say
No Revenue And Widening LossesThe absence of reported revenue through 2025 shows that Alpha Tau remains commercially pre-revenue, while widening losses indicate substantial operating costs without an offsetting sales base. This leaves future financial performance dependent on successful clinical development and eventual commercialization.
Persistent Cash BurnSustained operating and free-cash-flow outflows mean the company cannot currently fund its activities from internal cash generation. Continued development spending therefore increases reliance on external financing, making liquidity and capital availability important constraints over the coming quarters.
Unapproved Clinical-Stage TechnologyAlpha DaRT remains unapproved for routine clinical use, so the business has not yet established a validated commercial product or recurring treatment revenue. Regulatory and clinical milestones remain essential before broader adoption, reimbursement and durable commercial scale can develop.
Alpha Tau News
DRTS FAQ
What was Alpha Tau’s price range in the past 12 months?
Alpha Tau lowest stock price was 4150.00 and its highest was 4800.00 in the past 12 months.
What is Alpha Tau’s market cap?
Alpha Tau’s market cap is ₪4.07B.
When is Alpha Tau’s upcoming earnings report date?
Alpha Tau’s upcoming earnings report date is Nov 24, 2026 which is in 68 days.
How were Alpha Tau’s earnings last quarter?
Alpha Tau released its earnings results on Aug 10, 2026. The company reported -150.523 earnings per share for the quarter, missing the consensus estimate of -42.447 by -108.075.
Is Alpha Tau overvalued?
According to Wall Street analysts Alpha Tau’s price is currently Undervalued.
Does Alpha Tau pay dividends?
Alpha Tau does not currently pay dividends.
What is Alpha Tau’s EPS estimate?
Alpha Tau’s EPS estimate is -44.25.
How many shares outstanding does Alpha Tau have?
Alpha Tau has 90,325,874 shares outstanding.
What happened to Alpha Tau’s price movement after its last earnings report?
Alpha Tau reported an EPS of -150.523 in its last earnings report, missing expectations of -42.447. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Alpha Tau?
Currently, no hedge funds are holding shares in IL:DRTS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alpha Tau Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
₪5,449.49 (― Downside)
₪5,449.49 (― Downside)
Blogger Sentiment
Bullish
IL:DRTS Sentiment 87%
Sector Average 62%
Sector Average 62%
Insider Transactions
Sold Shares
Worth ₪3.7M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
289.63%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
21.00%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Alpha Tau
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company is headquartered in Jerusalem, Israel.
DRTS Stock 12 Month Forecast
Average Price Target
5,449.49